Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A9YA
|
|||
| Former ID |
DAP000044
|
|||
| Drug Name |
Dutasteride
|
|||
| Synonyms |
Avodart; Avolve; Duagen; Dutasteride [USAN]; GG 745; GI 198745; Avidart (TN); Avodart (TN); Avodart, Dutasteride; Avolve (TN); Duagen (TN); Duprost (TN); Dutagen (TN); Dutas (TN); GG-745; GI-198745; GI-198745X; Dutasteride (JAN/USAN/INN); N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; Alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide; (1S,3aS,3bS,5aR,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (5-alpha,17-beta)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide;dutasteride; (5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Benign prostatic hyperplasia [ICD-11: GA90; ICD-10: N40; ICD-9: 600] | Approved | [1], [2] | |
| Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 3 | [1], [2] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
GSK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H30F6N2O2
|
|||
| Canonical SMILES |
CC12CCC3C(C1CCC2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CCC5C3(C=CC(=O)N5)C
|
|||
| InChI |
1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1
|
|||
| InChIKey |
JWJOTENAMICLJG-QWBYCMEYSA-N
|
|||
| CAS Number |
CAS 164656-23-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
12014955, 14836607, 14909902, 17194796, 17397907, 43529678, 46504830, 53787436, 57371871, 71824992, 79317270, 81092907, 85709776, 91145910, 91612910, 99437024, 103770952, 104179082, 114787740, 118046363, 124757077, 125163881, 125311722, 126596711, 131343417, 135109202, 135684130, 136183917, 136367959, 136375517, 136980377, 137005555, 137181708, 142643797, 144115926, 144205752, 152059555, 152063850, 162036214, 162175331, 163797282, 165698504, 172093501, 174477509, 174527666, 175265390, 176484953, 179150039, 187051760, 210274902
|
|||
| ChEBI ID |
CHEBI:521033
|
|||
| ADReCS Drug ID | BADD_D00736 | |||
| SuperDrug ATC ID |
G04CB02
|
|||
| SuperDrug CAS ID |
cas=164656239
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7457). | |||
| REF 2 | 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):389-402. | |||
| REF 3 | The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.